What is the debt of Insmed this year?
Insmed has a debt level of 702.57 USD this year.
Insmed Debt 2024
Insmed Debt
702.57 USD
Ticker
INSM
ISIN
US4576693075
WKN
A1JJA3
In 2024, Insmed's total debt was 702.57 USD, a 755.76% change from the 82.1 USD total debt recorded in the previous year.
Insmed Aktienanalyse
What does Insmed do?
Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Insmed's Debt Structure
Insmed's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Insmed's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Insmed’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Insmed’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Insmed stock
What was the debt of Insmed compared to the previous year?
The debt of Insmed has increased by 755.76% compared to the previous year increased.
What are the consequences of high debt for investors in Insmed?
High debt can pose a risk for investors of Insmed, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Insmed?
Low debt means that Insmed has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Insmed affect the company?
An increase in debt of Insmed can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Insmed affect the company?
A reduction in debt of Insmed can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Insmed?
Some factors that can influence the debt of Insmed include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Insmed so important for investors?
The debts of Insmed are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Insmed take to change the debt?
To change the debt, Insmed can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Insmed pay?
Over the past 12 months, Insmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insmed is expected to pay a dividend of 0 USD.
What is the dividend yield of Insmed?
The current dividend yield of Insmed is .
When does Insmed pay dividends?
Insmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Insmed?
Insmed paid dividends every year for the past 0 years.
What is the dividend of Insmed?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Insmed located?
Insmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Insmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Insmed from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Insmed pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Insmed in the year 2023?
In the year 2023, Insmed distributed 0 USD as dividends.
In which currency does Insmed pay out the dividend?
The dividends of Insmed are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Insmed
Our stock analysis for Insmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
